News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Signs MoUs with Shri Krishna Ayush University and Dabur India
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Subscribe To Our Newsletter & Stay Updated
